Familial polycythemia vera with non-germ line JAK2V617F mutation sparing the abnormal and clonal granulopoiesis [14]

Leukemia

Volumn 21, Issue 12, 2007, Pages 2566-2568

  Hussein, K ^a   Bock, O ^a   Ballmaier, M ^a   Gohring G ^a   Steinemann, D ^a   Lehmann, U ^a   Kemper, J ^b   Buhr, T ^a   Kreipe, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Medical Practice for Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; CD177 ANTIGEN; JANUS KINASE 2; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; BONE MARROW BIOPSY; CASE REPORT; CELL LEVEL; CELL LINEAGE; CHROMOSOME ANALYSIS; CLONAL VARIATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; FAMILIAL DISEASE; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GERM LINE; GRANULOCYTE; GRANULOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MUTATIONAL ANALYSIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

EID: 36348929877     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404846     Document Type: Letter

References (8)

1. Bellanné-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
2. Bock O, Busche G, Koop C, Schroter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the IH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn 2006; 8: 170-177.
3. Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G et al. Biomarker analysis in polycythemia vera under interferon-alpba treatment: Clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 2007; 86: 239-244.
4. Bock O, Serinsoz E, Neusch M, Schlue J, Kreipe H. The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders. Br J Haematol 2003; 123: 472-474.
5. Steinemann D, Skawran B, Becker T, Tauscher M, Weigmann A, Wingen L et al. Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization. Clin Gastroenterol Hepatol 2006; 4: 1283-1291.
6. Hussein K, Brakensiek K, Ballmaier M, Bormann M, Gohring G, Buhr T et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006; 77: 539-541.
7. Zehentner BK, Loken MR, Wells DA. JAK2(V617F) mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol 2006; 81: 806-807.
8. Kralovics R, Teo S-S, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380.